“Increasing Shift towards Micro-Invasive Devices”
The glaucoma surgery devices market is witnessing significant growth, driven by the increasing demand for minimally invasive glaucoma surgeries (MIGS) and technological advancements. One key trend is the shift towards micro-invasive devices that offer quicker recovery times and fewer complications compared to traditional methods. For instance, the iStent Inject from Glaukos has gained FDA approval as a MIGS option, offering patients a safer, less invasive alternative to trabeculectomy. These devices are designed to reduce intraocular pressure (IOP) more effectively with reduced risk of side effects, making them highly attractive for both patients and surgeons. The advancement in glaucoma drainage devices and laser systems, such as the iTrack Advance canaloplasty system, further reflects this trend of improving surgical precision and minimizing recovery periods. As MIGS devices continue to evolve, the market is expanding, with key players such as Novartis and AbbVie leading the way, creating more innovative solutions to manage glaucoma with better patient outcomes.